Abstract: A compound of Formula I, is provided. In Formula I, one of Z1, Z2, and Z3 is N and the remainder are C; each of L1 and L2 is independently selected from a direct bond and a linking group; at least one of R1, R2, RA, RB, RC, RD, and RE comprises a group R* having a structure selected form the group consisting of Formula II, -Q(R3)(R4)a(R5)b, Formula III, and Formula IV, Each R, R?, R?, R1, R2, R3, R4, R5, RA, RB, RC, RD, RE, RF, RG, and RH is independently hydrogen or a General Substituent, with the proviso that group R* is not adamantyl. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Compositions and methods for detecting pathogens are provided. In one aspect, a method for detecting a pathogen on or within an object comprises: providing a detection agent configured to generate a visible indication when exposed to the pathogen; contacting the detection agent with the object; and visually detecting the presence or absence of the visible indication, wherein the presence of the visible indication indicates that the pathogen is present on or within the object.

Abstract: The present invention includes novel compounds of the formula wherein: X is absent, or trans or cis CHCH; R1 is (C1-C10)alkyl unsubstituted or substituted by one to three hydroxy, (C2-C10)alkenyl unsubstituted or substituted by one to three hydroxy, (C2-C10)alkynyl unsubstituted or substituted by one to three hydroxy, or aryl unsubstituted or substituted by one to three hydroxy; R2 is hydrogen, alkyl or aryl, wherein R1 and R2 when taken together form a (C2-C10)cycloalkyl unsubstituted or substituted by one to three hydroxy; and R3 and R4 are, independently of each other, H, halogen, or wherein: P and R are each independently selected from CH2, CH2CH2 and CH2CHT, wherein T is alkyl; Q is O, S, NH or NCH3; and Y is absent or —CH2CH2)nO—, and n=1 or 2; with the proviso that at least one of R3 and R4 is halogen, and that when R4 is halogen, R3 is hydrogen and Y is absent, neither R1 nor R2 are alkyl; or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.

Abstract: Compounds of formula 1 modulate the activity of Rho C: wherein n is 2 to 5, inclusive; R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently H, halo, lower alkyl, lower alkoxy, lower alkylamino, trifluoromethyl, nitro, lower alkylthio, or two adjacent residues form cycloalkyl, cycloalkenyl, aryl, or lower alkylenedioxy; and pharmaceutically acceptable salts thereof.

Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.

Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.

Abstract: Compounds of formula 1 modulate the activity of Rho C: 1

Abstract: The present invention relates to dihydro derivatives of the uridyl peptide antibiotics mureidomycin, pacidimycin and napsamycin which have antibiotic activity against a number of bacterial strains including strains resistant to current therapeutic antibiotics.

Abstract: Compounds of the invention have the structure D—L—A*, where L is a linking moiety that maintains D and A in a configuration compatible with FRET, D is a fluorescent donor moiety capable of causing an acceptor moiety to fluoresce by FRET, and A* is a fluorescent acceptor moiety capable of accepting energy from the donor moiety by FRET and fluorescing only after cleavage of one or more labile groups to provide acceptor A. These compounds are useful as fluorescent substrates for detection of enzymes in vivo.

Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Abstract: The invention provides novel antibiotics of the pacidamycin group of uridyl peptide antibiotics and methods of preparing and using those compounds.

Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.

Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.

Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Abstract: The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.

Abstract: The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.